Health care costs and resource utilization among commercially insured adult patients with hemophilia A managed with FVIII prophylaxis in the United States

Health care costs and resource utilization among commercially insured adult patients with hemophilia A managed with FVIII prophylaxis in the United States

BACKGROUND: Standard of care for patients with severe hemophilia A (HA) is life-long prophylaxis with factor VIII (FVIII) concentrate or other hemostatic agents. Published literature highlights a wide range of treatment costs for patients with HA. OBJECTIVE: To estimate average annual health care co...

Full description

Bibliographic Details
Main Authors: Adamski, K. (Author), Chen, E. (Author), Cook, K. (Author), Croteau, S.E (Author), Garrison, L.P., Jr (Author), Hinds, D. (Author), Sammon, J. (Author), Sendhil, S.R (Author), Solari, P. (Author), Thornburg, C.D (Author), Vembusubramanian, M. (Author)
Format: Article
Language:English
Published: NLM (Medline) 2022
Subjects:
adult
Adult
blood clotting factor 8
Factor VIII
health care cost
Health Care Costs
hemophilia A
Hemophilia A
hemostatic agent
Hemostatics
human
Humans
male
Male
Retrospective Studies
retrospective study
United States
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items